news

Drug compound used to overcome chemotherapy resistance in mice

Researchers testing 2-deoxy-D-glucose in mouse models of ovarian cancer report that the compound significantly improves the effectiveness of the chemotherapy drug, carboplatin.

Chemotherapy - Mice in lab

An international research team has discovered that chemotherapy resistance in an ovarian cancer subtype can be overcome in mice by using low doses of a drug which slows cell growth.

Led by scientists from Mater Research – The University of Queensland, Australia, the researchers found that 2-deoxy-D-glucose could be used at very low levels to significantly improve the effectiveness of the chemotherapy drug, carboplatin, in treating laboratory models of clear cell ovarian cancer.

According to the team, their work provides the rationale for a clinical trial to evaluate the use of low-dose 2-deoxy-D-glucose in treating patients with this type of cancer.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

“The key finding from our study is that low levels of 2-deoxy-D-glucose markedly improved the efficacy of carboplatin against pre-clinical models of this ovarian cancer. Our pre-clinical work used cells taken from patient tumours, so we were very encouraged that we could use such a low dose of 2-deoxy-D-glucose to overcome resistance to chemotherapy in this cancer and stop tumour growth. This drug has been trialled previously in other cancers, but we were able to use a 10-fold lower dose than previously reported so that it’s safer for patients and is less likely to cause side-effects,” said principal investigator, Professor John Hooper, from the Translational Research Institute (TRI), Australia.

The authors of the study explain that this method disrupted the tumour from utilising glycogen in both chemo-sensitive TOV21G and chemo-resistant OVTOKO cell lines. 

The team is hoping to begin trialling the treatment combination in patients within the next 12 months. 

The results were published in Cancers

Leave a Reply

Your email address will not be published. Required fields are marked *